Citi still bullish on Ambit despite no AA for quizartinib

Citi maintains a Buy rating on Ambit Biosciences (AMBI -35.2%).

Although Citi reportedly says AA for quizartinib wasn't baked into the share price, today's sell-off seems to tell a different story.

Price target lowered to $17 from $19.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs